Verrica Pharmaceuticals INC Form 4 insider transactions

Paul B. Manning, a director and 10% owner of Verrica Pharmaceuticals, transferred shares to family trusts following the termination of a Grantor Retained Annuity Trust.

Christopher G. Hayes, Chief Legal Officer of Verrica Pharmaceuticals, sold shares to cover statutory tax withholding obligations related to the settlement of restricted stock units.

Gary Goldenberg, Chief Medical Officer of Verrica Pharmaceuticals, sold shares to cover statutory tax withholding obligations related to the settlement of restricted stock units.

Joe Bonaccorso, Chief Commercial Officer of Verrica Pharmaceuticals, sold shares to cover statutory tax withholding obligations related to the settlement of restricted stock units.

Verrica Pharmaceuticals' CFO, Terry Kohler, sold shares of common stock to cover statutory tax withholding obligations related to the settlement of restricted stock units.

Verrica Pharmaceuticals' CEO, Ted White, sold shares of common stock to cover statutory tax withholding obligations related to the settlement of restricted stock units.

Verrica Pharmaceuticals' CEO, Ted White, sold shares of common stock to cover statutory tax withholding obligations related to the settlement of restricted stock units.

Joe Bonaccorso, Chief Commercial Officer of Verrica Pharmaceuticals, sold shares to cover statutory tax withholding obligations related to the settlement of restricted stock units.

Gary Goldenberg, Chief Medical Officer of Verrica Pharmaceuticals, sold shares of common stock to cover statutory tax withholding obligations related to the settlement of restricted stock units.

Christopher G. Hayes, Chief Legal Officer of Verrica Pharmaceuticals, sold shares of common stock to cover statutory tax withholding obligations related to the settlement of restricted stock units.

Director Lawrence Eichenfield acquired 20,000 stock options in Verrica Pharmaceuticals on June 6, 2024, according to a Form 4 filing.

Mark A. Prygocki Sr., a director of Verrica Pharmaceuticals, acquired stock options for 20,000 shares on June 6, 2024.

Director Diem Nguyen acquired stock options for 20,000 shares of Verrica Pharmaceuticals on June 6, 2024.

Director Craig Ballaron acquired 20,000 stock options in Verrica Pharmaceuticals Inc. on June 6, 2024, according to a Form 4 filing.

Christopher G. Hayes, Chief Legal Officer of Verrica Pharmaceuticals, reports acquisition of common stock and stock options.

Gary Goldenberg, Chief Medical Officer of Verrica Pharmaceuticals, reports acquisition of shares and stock options.

Verrica Pharmaceuticals' CFO, Terry Kohler, was granted stock options and restricted stock units on March 15, 2024, as reported in a Form 4 filing with the SEC.

Joe Bonaccorso, Chief Commercial Officer of Verrica Pharmaceuticals, reports acquisition of shares and stock options.

Ted White, CEO of Verrica Pharmaceuticals, acquired shares and options in the company on March 15, 2024, according to a Form 4 filing.